REGENXBIO Inc. (NASDAQ:RGNX) is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 1.01 per share.
Looking ahead, the full year loss are expected at $ 2.92 per share on the revenues of $ 115.12 million.
Previous Quarter Performance
REGENXBIO Inc. revealed loss for the second quarter of $ 0.91 per share, from the revenue of $ 16.57 million. The quarterly revenues increased 110.28 percent compared with the same quarter last year. Street analysts expected REGENXBIO Inc. to report loss of $ 0.89 per share on revenue of $ 22.07 million for the second quarter. The bottom line results missed street analysts by $ 0.02 or 2.25 percent, at the same time, top line results fell short of analysts by $ 5.5 million or 24.92 percent.
Stock Performance
Shares of REGENXBIO Inc. traded up $ 0.76 or 2.72 percent on Tuesday, reaching $ 28.69 with volume of 331.80 thousand shares. REGENXBIO Inc. has traded high as $ 28.96 and has cracked $ 27.69 on the downward trend
According to the previous trading day, closing price of $ 28.69, representing a 39.44 % increase from the 52 week low of $ 20.03 and a 49.19 % decrease over the 52 week high of $ 54.97.
The company has a market capital of $ 1.07 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
REGENXBIO Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.regenxbio.com
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The companys lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration.
